Lion TCR

We were honored to extend a warm welcome to Dr. Koh Poh Koon, Senior Minister of State and Director of Business China, and Mr. Alvin Tan, Minister of State for Trade and Industry, accompanied by their esteemed delegation, to our Guangzhou subsidiary on April 23, 2024. During their visit, our CEO, Dr. Peng Xiaoming, had the privilege of presenting Lion TCR’s pioneering mRNA-based TCR-T cell therapy for solid tumours, and also highlighted our significant progress in clinical trials. At Lion TCR, our dedication extends beyond advancing our flagship product for advanced liver cancer. We're committed to addressing the challenges of chronic hepatitis B, early and mid-stage liver cancer, and cancer prevention, while also developing accessible off-the-shelf solutions. Senior Minister of State Koh conveyed his anticipation for sustained collaboration between Chinese and Singaporean enterprises in driving innovation within the biotechnology landscape. He encouraged Lion TCR to uphold its steadfast commitment to innovation. Stay tuned for more updates as we continue our pursuit of pioneering biotechnology solutions! #tcr #tcrt #celltherapy #hbv #mRNA #hcc #solidtumours

Unveiling Cutting-Edge Precision Medicine Advances at APASL 2024 Kyoto: Leveraging mRNA-Based HBV-TCR T Cell Therapy to Elicit Broad HBV T-Cell Response in Hepatocellular Carcinoma   We are pleased to share some important updates from the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024 Kyoto - The Center of Hepatology, which took place from March 27-31, 2024, in the picturesque city of Kyoto, Japan. APASL serves a region with the world's largest population, where 70% of global liver disease patients are concentrated. Since its establishment in 1978 in Singapore, APASL remains to at the forefront of liver and biliary tract disease research for the Asia Pacific region.   At this prestigious event, our work was selected as Oral Presentation. Lead Principal Investigator, Dr Thinesh Lee Krishnamoorthy from Singapore General Hospital, presented our ongoing Phase 1b study utilizing mRNA based HBV-specific TCR T cells for patients with primary hepatocellular carcinoma (HCC), elucidating the immunological changes induced by our innovative therapy. This study represents a groundbreaking use of mRNA technology in immunotherapy and underscores the safety and immunological responses to T cells expressing transiently HBV-TCR in patients with Chronic HBV infection and HCC. Our findings suggest the potential of mRNA HBV-specific TCR T cells to evoke a broader immune response through secondary immune responses and epitope spreading, thereby further enhancing desirable efficacy.   As we reflect on this momentous occasion, we extend our heartfelt appreciation to the patients who have participated in this study as well as to our dedicated research teams at Singapore General Hospital, National Cancer Centre Singapore and Duke-NUS Medical School whose support continues to drive our mission forward.   We are proud to contribute to the fight against liver diseases in the Asia-Pacific region and beyond. Stay tuned as we continue to push the boundaries of medical innovation! #tcr #tcrt #hbv #HepatocellularCarcinoma #CellTherapy #immunotherapy #mRNA #firstinclass Images obtained from: https://lnkd.in/d26Nwc9H

Lion TCR and NUS Guangzhou Institute Sign Strategic Partnership for Research and Talent Development   Exciting news! Lion TCR has forged a strategic partnership with the National University of Singapore Guangzhou Research Translation and Innovation Institute (NUSGRTII) to jointly drive cutting-edge innovation in cell therapy, biomedical research and interdisciplinary AI.   Through this synergistic collaboration, we will harness our complementary strengths to establish a robust "industry-academia-research-application" ecosystem. By consolidating resources from government, industry, and academia, we aim to accelerate industrial upgrading, facilitate technology transfer, and propel breakthrough innovations.   At Lion TCR, we are excited to combine our clinical expertise in mRNA-based TCR T cell immunotherapies with NUS' world-class research capabilities. Leveraging our expertise in cell immunotherapy and AI-enabled target discovery, we will collaborate with NUS Guangzhou Institute on R&D innovations in biomedicine as well as interdisciplinary AI fields. Harnessing AI to uncover novel therapeutic targets holds promise to accelerate the drug development process. This synergy will catalyze our mission to develop potentially curative cell therapies for cancer patients.   The partnership encompasses multiple fronts - professional talent development, technology commercialization, and joint research projects at the frontiers of biomedical science and engineering. Dedicated teams from both partners will coordinate efforts, sharing resources and proprietary knowhow.   We look forward to a fruitful partnership that advances scientific boundaries and nurtures future leaders driving biomedical research and healthcare innovation. Together, we are well-positioned to translate cutting-edge innovations into pioneering clinical applications that improve human health.   Stay tuned for more updates on this exciting collaboration!   #biotech #celltherapy #tcr #immunotherapy #AI #innovation #academia #partnershipforprogress

Honored to be Nominated for Best Clinical Trials of the Year at ABEA 2024! We're honored to announce that Lion TCR has been nominated for the prestigious Asia-Pacific Biopharma Excellence Awards (ABEA) 2024 in the category of Best Clinical Trials of the Year! This recognition is a testament to our commitment to advancing cutting-edge clinical trials in the biopharma industry. The awards ceremony will take place in conjunction with the 2nd Annual Clinical Trials Festival Asia 2024 on March 20, 2024, at the Sands Expo & Convention Center in Singapore. This nomination reflects the hard work and dedication of our entire team at Lion TCR, and we're incredibly grateful for this acknowledgment within the industry. Voting Details: Your support means the world to us! Voting is open until February 2, 2024, and you can cast your vote for Lion TCR here: https://lnkd.in/g_WEgPYn Feel free to share the voting link within your networks and help us secure this accolade! Thank you for your ongoing support! #ClinicalTrials #BiopharmaExcellence #ABEA2024 #LionTCR #TCR #HBV #celltherapy #mRNA #hcc

We are excited to announce a new strategic partnership with MaxCyte, Inc. that will advance our TCR-T cell therapy pipeline. This license agreement gives Lion TCR worldwide rights to use MaxCyte's cutting-edge Flow Electroporation® technology and ExPERT platform for our clinical cell therapy programs. This deal supports our mission to become a global leader in mRNA-based TCR-T cell therapies for cancers and infectious diseases like chronic hepatitis B. MaxCyte's industry-leading electroporation systems will empower us to engineer T cells with higher efficiency, scalability, and functionality. Our lead candidate, LioCyx-M004, is an mRNA-encoded TCR-T cell therapy targeting hepatitis B-related hepatocellular carcinoma. It has already received Fast Track and Orphan Drug Designation from the FDA and is the world's first FDA-approved multi-center international trial of its kind. We're thrilled to collaborate with MaxCyte and its enabling platform technologies to fulfill our vision of making personalized immunotherapies available for all. This deal is an important step in bringing our potentially life-saving TCR-T cell therapies to patients globally. For more details, please read: https://lnkd.in/eT-tBZ7K

Lion TCR is thrilled to announce a significant milestone of clinching the T-Up Excellence Awards. This award, in recognition of remarkable contributions to the growth and innovation within Lion TCR and the broader Singapore biotech sector, have been presented to Dr. Lu-En Wai, Lion TCR's Senior Director of Research and Development, and Dr. Sarene Koh, Director of Technology and Manufacturing. For full press release, please refer to: https://lnkd.in/gXc5UghR

Lion TCR is delighted to announce our participation as a Gold Sponsor, Exhibitor and Presenter at the ASIAN NATIONAL CANCER CENTERS ALLIANCE (ANCCA) ANNUAL SCIENTIFIC CONFERENCE 2023 to be held on 02 to 03 November 2023, with the theme "Uniting Asia Against Cancer." Our Clinical Manager, Dr. Regina Wong (PhD), and Technology Manager, Dr. Shin Yi Tang, will be overseeing Lion TCR's booth, where they will be sharing the journey of Lion TCR from research and development to real-world application, along with providing insights into TCR T cell immunotherapy. Additionally, our Chief Operating Officer and Chief Medical Officer, Dr. Tina WANG Tingting, will deliver a presentation on "Lion TCR's Vision: Pioneering T Cell Therapies for Solid Tumors." We're honored to be part of this event that unites forces against cancer in Asia. If you're attending, make sure to visit our booth and join Dr. Tina's session to explore the groundbreaking work we're doing at Lion TCR. Together, we can make a difference in the fight against cancer! #CancerResearch #ANCCAConference #LionTCR #UniteAgainstCancer #TCRT #celltherapy

Lion TCR is thrilled to announce our participation as an Exhibitor at the Singapore Week of Innovation and Technology (SWITCH) from 31 Oct to 2 Nov! At LION TCR, we are at the forefront of cutting-edge biotech innovation in mRNA-based T cell immunotherapy, and SWITCH provides the perfect platform to showcase our groundbreaking work. Join us as we take you on a journey into the future of personalized medicine. We can't wait to connect with like-minded individuals who are passionate about driving innovation in the biotech sector. Visit our booth @K10 (A*STAR booth) to meet our Senior Director of R&D Dr. Lu-En Wai and Director of Strategy & BD Dr. Priscilla Wong to learn more about our latest research, foster potential collaborations, and embark on a transformative journey into the dynamic landscape of healthcare innovation, with a spotlight on the cutting-edge domain of mRNA-based TCR-T immunotherapy. See you at SWITCH 2023! #LIONTCR #SWITCH2023 #TCR #mRNA #CellTherapy #PersonalizedMedicine #Immunotherapy

Today, Dr. Tina WANG Tingting, COO/CMO of Lion TCR, delivered a presentation during the BioCon Asia 2023-ACGT conference at Sofitel Singapore City Centre. She provided insights into the cell therapy landscape, shedding light on the hurdles and prospects within the industry. Additionally, Dr. Tina showcased the evolution of Lion TCR's TCR T cell therapy for liver cancer, detailing its progression from laboratory research to practical application. #hbv #tcrt #immunotherapy #personalized #translation #livercancer #hcc #liontcr

Celebrating the Nobel Prize-Winning Pioneers of mRNA Technology In a momentous recognition of scientific achievement, Katalin Kariko and Drew Weissman have been awarded the Nobel Prize in Physiology or Medicine for their groundbreaking work that laid the foundation for the rapid development of mRNA-based vaccines, including those by Moderna Inc. and the Pfizer Inc.-BioNTech SE partnership. Their research, dating back to 2005, addressed a significant challenge in mRNA technology by mitigating inflammation, which had been a major hurdle in its application. By doing so, they unlocked the potential of mRNA to stimulate cells to produce the components needed for a vaccine, revolutionizing the field and enabling the development of COVID-19 vaccines in record time. Their dedication and persistence, despite initial setbacks and years of relative obscurity, have made a profound impact on global health. And speaking of revolutionary applications of mRNA technology, it is also possible to utilise mRNA for work in anticancer treatment, still a major unmet medical need worldwide. At Lion TCR, we harness mRNA to encode T cell receptors for cutting-edge cell therapy for HBV-related liver cancer. Our HBV specific TCR T cell therapy has shown early promise as a safe yet effective therapy. What's even more fascinating is the potential of mRNA technology to pave the way for 'off-the-shelf' immunotherapies. This visionary approach allows for TCR T cell generation in situ, unlocking possibilities for more accessible and personalized treatments. This Nobel Prize serves as a testament to the power of scientific discovery, resilience, and the impact it can have on humanity. It reminds us that breakthroughs often emerge from dedication and collaboration, and that even the most challenging problems can be solved with ingenuity and perseverance. Congratulations to Katalin Kariko and Drew Weissman for their well-deserved recognition, and let's continue to support and invest in the incredible potential of mRNA technology, with Lion TCR leading the way to transform healthcare and improve lives worldwide. #mrna #tcrt #hbv #celltherapy #personalized #immunotherapy